Literature DB >> 16715140

Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells.

S Paruchuri1, M Mezhybovska, M Juhas, A Sjölander.   

Abstract

The cysteinyl leukotriene1 (CysLT1) receptor (CysLT1R) enhances survival and proliferation of intestinal cells via distinct pathways. Here, we have demonstrated that there is significant endogenous production of CysLTs from both non-tumour- and tumour-derived intestinal epithelial cells. Treatment of two non-tumour cell lines, Int 407 and IEC-6, with CysLT1R antagonists led to shrinkage and detachment of cells, confirmed as apoptotic cell death, and a dose-dependent reduction in proliferation. However, in the tumour intestinal cell lines Caco-2, SW480, HCT-116 and HT-29, treatment with CysLT1R antagonists significantly reduced proliferation, but had no effect on apoptosis. A unique characteristic of intestinal cancer cells is the presence of nuclear CysLT1Rs, which are inaccessible to receptor antagonists. In these cells, inhibition of the endogenous production of CysLTs indirectly, by 5-lipoxygenase inhibition, impaired CysLT1R signalling throughout the cell, and resulted in apoptosis of the tumour cells. These data reveal the existence of constitutive CysLT1R signalling that mediates both survival and proliferation in intestinal cells. Importantly, we propose that tumour-derived intestinal cells are resistant to CysLT1R antagonist-induced apoptosis, a phenomena that could be explained by nuclear CysLT1R signalling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715140     DOI: 10.1038/sj.onc.1209666

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

Review 1.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

Review 2.  Critical roles of G protein-coupled receptors in regulating intestinal homeostasis and inflammatory bowel disease.

Authors:  Zhongsheng Feng; Ruicong Sun; Yingzi Cong; Zhanju Liu
Journal:  Mucosal Immunol       Date:  2022-06-22       Impact factor: 8.701

3.  A Dual Role for Cysteinyl Leukotriene Receptors in the Pathogenesis of Corneal Infection.

Authors:  Thomas W Carion; Yuxin Wang; Ashten Stambersky; Abdul Shukkur Ebrahim; Elizabeth A Berger
Journal:  J Immunol       Date:  2022-04-25       Impact factor: 5.426

Review 4.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

5.  P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells.

Authors:  Yongfeng Jiang; Laura Borrelli; Brian J Bacskai; Yoshihide Kanaoka; Joshua A Boyce
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

6.  Activity of the leukotriene pathway in Barrett's metaplasia and oesophageal adenocarcinoma.

Authors:  James David Shutt; Philip Boger; James Richard Neale; Praful Patel; Anthony Peter Sampson
Journal:  Inflamm Res       Date:  2012-08-01       Impact factor: 4.575

7.  Ligand-induced tyrosine phosphorylation of cysteinyl leukotriene receptor 1 triggers internalization and signaling in intestinal epithelial cells.

Authors:  Ladan Parhamifar; Wondossen Sime; Yuliana Yudina; Frederik Vilhardt; Matthias Mörgelin; Anita Sjölander
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

8.  Beta-catenin is involved in alterations in mitochondrial activity in non-transformed intestinal epithelial and colon cancer cells.

Authors:  M Mezhybovska; Y Yudina; A Abhyankar; A Sjölander
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

9.  CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer.

Authors:  Sayeh Savari; Minghui Liu; Yuan Zhang; Wondossen Sime; Anita Sjölander
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

10.  BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation.

Authors:  R Hennig; T Osman; I Esposito; N Giese; S M Rao; X-Z Ding; W-G Tong; M W Büchler; T Yokomizo; H Friess; T E Adrian
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.